NewcelX Ltd(NCEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 52.9% | Shs Outstand | 5.4M | Perf Week | -0.31% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 49.15% | Insider Trans | 5.03% | Shs Float | 2.5M | Perf Month | -11.62% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.65 | Inst Own | 0.23% | Short Float | 0.59% | Perf Quarter | -30.01% |
| Income | - | P/S | - | EPS this Y | 45.37% | Inst Trans | 28.27% | Short Ratio | 1.06 | Perf Half Y | 42.34% |
| Sales | - | P/B | 2.64 | EPS next 5Y | 30.03% | ROA | - | Short Interest | 0.02M | Perf YTD | 55.83% |
| Book/sh | 1.12 | P/C | 22.45 | EPS past 3/5Y | 81.39% 60.94% | ROE | - | 52W High | -85.05% ($19.80) | Perf Year | -84.58% |
| Cash/sh | 0.13 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 61.8% ($1.83) | Perf 3Y | -98.97% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 77.07% | Gross Margin | - | Volatility(W/M) | 5.85% 6.96% | Perf 5Y | -99.7% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.32 | EPS Q/Q | 86.03% | Profit Margin | - | RSI (14) | 43.37 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.32 | Sales Q/Q | - | SMA20 | -4.03% ($3.08) | Beta | 1.06 | Target Price | $23 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/09/02 | SMA50 | -9% ($3.25) | Rel Volume | 0.51 | Prev Close | $2.86 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -3.44% ($3.07) | Avg Volume(3M) | 0.01M | Price | $2.96 |
| IPO | 2021/1/29 | Option/Short | No/Yes | Trades | 72 | Volume | 7,212 | Change | 3.52% |
🧬 NewcelX () is a clinical-stage biotech company developing cell therapies targeting type 1 diabetes and neurodegenerative diseases. Established through the merger of Israel's Kadimastem and Switzerland's NLS Pharmaceutics, it operates as a Bi-Continental platform building a regenerative medicine pipeline centered on insulin-secreting cells (IsletRx) and astrocyte-based cell therapies (AstroRx). It is a small-cap biotech stock.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded less than usual That is 51% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +45.4% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.2%.
Tap to view numbers
It ranks #480 of 592 in the industry
Based on market cap of $16M.
FAQ
What kind of company is NCEL?
NCEL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NCEL?
The market cap of NCEL is approximately $16M, ranking 5,341 within its sector.
What is the 52-week high and low for NCEL?
NCEL has recorded a 52-week high of $19.80 and a low of $1.83.
